PARSIPPANY, N.J., Sept. 20, 2017 (GLOBE NEWSWIRE) — Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) (the “Company” or “Interpace”), a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services for improved patient diagnosis and management, today announced that on September 18, 2017, the Company received a letter from The Nasdaq Stock Market LLC stating that the Company has regained compliance with Listing Rule 5605(c)(2), which requires the Company to maintain three audit committee members on its Board of Directors. Jack E. Stover, President and CEO of Interpace Diagnostics, stated, “We are pleased that the Company has regained […]
This post first appeared on Bloggerwave Inc. Is In The StockGuru Spotlight For October 22, 2010 | StockGuru SmallCap Alerts On Penny Stocks, please read the originial post: here